Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
Federal Trade Commission
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,614,560

« Back to Dashboard

Summary for Patent: 5,614,560

Title: Method of preventing NMDA receptor-mediated neuronal damage
Abstract:Disclosed is a method for reducing non-ischemic NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a compound of the formula shown in FIG. 1 (or a physiologically-acceptable salt thereof), wherein R.sub.1 includes an amino group, R.sub.2 -R.sub.17 are independently H or a short chain aliphatic group comprising 1-5 carbons, and R.sub.4 and R.sub.10 also may (independently) be a halogen or an acyl group. Also disclosed is a screen for antagonists of NMDA receptor mediated neurotoxicity which have an enhanced prospect for being clinically tolerated and selective against such neurotoxicity.
Inventor(s): Lipton; Stuart A. (Newton, MA)
Assignee: Children's Medical Center Corporation (Boston, MA)
Application Number:08/419,672
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 5,614,560

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia6351698► Subscribe
Canada2143752► Subscribe
Germany69027026► Subscribe
Germany69229598► Subscribe
Germany69330387► Subscribe
Germany69334035► Subscribe
Denmark0660707► Subscribe
Denmark0661973► Subscribe
European Patent Office0465565► Subscribe
European Patent Office0557290► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus